Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Effectively managing hepatorenal syndrome-acute kidney injury (HRS-AKI) remains a critical challenge, however availability of the first FDA-approved therapy and expanding evidence to guide its use in practice are reshaping treatment strategies.

In Part 2 of this two-part video podcast series, you will join an insightful conversation with two nationally recognized HRS-AKI experts as they discuss how to differentiate treatment options and share best practices for patient pre-assessment and post-treatment monitoring to ensure safe and effective care. You will walk away with practical, evidence-based insights into applying guideline-directed therapy and optimizing care for patients with HRS-AKI.

• Evaluate the indications, efficacy and safety profiles, and administration considerations of guideline-recommended vasoconstrictor therapies for HRS-AKI
• Integrate best practices for pre-treatment assessment and post-treatment monitoring of patients receiving vasoconstrictor therapy for HRS-AKI

AGENDA

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Todd Frederick, MD (Speaker)
  
  Advisory Board or Panel – Ipsen, Madrigal, Mallinckrodt
  Consultant – Mallinckrodt, Miromatrix
  Grants / Research Support – AstraZeneca, Mallinckrodt, River 2 Renal, Salix
  Speakers Bureau or other Promotional Education – Madrigal
  Stock / Shareholder (self- managed) – Madrigal
  The relationships reported above are related to the following therapeutic area: Gastroenterology
• Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Planner)
  
  Speakers Bureau or other Promotional Education – Astellas, AstraZeneca, Bristol-Myers Squibb, CTI, Coherus, DSI, Dova, Eli Lilly and Company, Gilead Sciences, Morphosys, Pfizer
  The relationships reported above are related to the following therapeutic area: Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Amanda Chaney, DNP, APRN, FAANP, AF-AASLD (Speaker)
• Annette Sophin, MSMM, PA-C (Reviewer)
• Abimbola Farinde, PhD, PharmD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.